What is PharmaCyte Biotech?
PharmaCyte Biotech, Inc. is a biotechnology firm headquartered in Las Vegas, Nevada, dedicated to the advancement and commercialization of cellular therapies for oncological and diabetic conditions within the United States. The company's core technology, Cell-in-a-Box, is a patented cellulose-based live cell encapsulation system designed to facilitate the delivery of therapeutic agents. PharmaCyte is actively pursuing treatments for advanced pancreatic cancer and various forms of diabetes, including Type 1 and insulin-dependent Type 2, alongside exploring cannabis-derived compounds for cancer treatment. Formerly known as Nuvilex, Inc., the company adopted its current name in 2015 to reflect its strategic focus.
How much funding has PharmaCyte Biotech raised?
PharmaCyte Biotech has raised a total of $7M across 1 funding round:
Private Equity
$7M
Private Equity (2025): $7M, investors not publicly disclosed
What's next for PharmaCyte Biotech?
The recent major strategic investment signals a pivotal phase for PharmaCyte Biotech, likely enabling the company to accelerate its clinical trial pipeline, expand its research and development capabilities, and potentially scale its manufacturing operations. This infusion of capital is expected to bolster its efforts in bringing its proprietary cellular therapies for cancer and diabetes to market, positioning the company for significant growth and further validation in the competitive biotechnology landscape.
See full PharmaCyte Biotech company page
